People: Tissue Therapies Ltd (TIS.AX)

TIS.AX on Australia Stock Exchange

0.28AUD
10 Jul 2014
Price Change (% chg)

$-0.01 (-3.45%)
Prev Close
$0.29
Open
$0.28
Day's High
$0.29
Day's Low
$0.28
Volume
141,775
Avg. Vol
132,727
52-wk High
$0.39
52-wk Low
$0.12

Search Stocks

Summary

Name Age Since Current Position

Roger Clarke

2003 Non-Executive Chairman of the Board

Steven Mercer

2006 Chief Executive Officer, Managing Director, Executive Director

Drummond McKenzie

Chief Financial Officer, Company Secretary

Zee Upton

Chief Scientific Officer

Andrew Thelwell

Managing Director - EU Commercial Operations

Eva-Lisa Heinrichs

Medical Director - Global Medical Affairs

Saskia Jo

Corporate Accountant

Nigel Johnson

Operations Director

Hedie Meka

Regulatory & Intellectual Property Manager

Gary Shooter

Director of Research and Development

Brian Ziegelaar

International Product Manager

Iain Ross

2012 Director

Melvyn Bridges

2009 Non-Executive Director

Cherrell Hirst

2009 Non-Executive Director

Biographies

Name Description

Roger Clarke

Mr. Roger Brian Clarke has been Non-Executive Chairman of the Board of Tissue Therapies Ltd since November 6, 2003. He has over 30 years of commercial experience, principally in the investment banking industry, with responsibilities in fund management, banking and corporate finance, and involvement in a number of initial public offerings, capital raisings and corporate transactions. He is Chairman of Board of Advice, RBS Morgans Limited; Chairman of NextDC Limited, Coalbank Limited and MTQ Insurance Ltd; Director of Trojan Equity Limited and Maverick Drilling and Exploration Limited. Mr. Clarke holds a Bachelor of Commerce degree and is a Chartered Accountant. He was a Director of PIPE Networks Limited. He is Chairman of the Audit and Risk Management Committee and Member of Remuneration Committee and Nomination Committee at the Company.

Steven Mercer

Dr. Steven J. Mercer has been Chief Executive Officer, Managing Director and Executive Director of Tissue Therapies Ltd since May 10, 2006. He has been CEO of Tissue Therapies Ltd since late September 2004. During this time, Tissue Therapies has developed multiple formulations of synthetic proteins and produced VitroGro ECM for the treatment of hard to heal wounds to a commercial scale. The Company has conducted successful clinical trials, submitted an application for approval for sale in the EU (CE Mark) and applications to start US FDA clinical trials for the treatment of venous and diabetic ulcers. He is a Fellow of the Australian Institute of Company Directors and a Registered Medical Practitioner.

Drummond McKenzie

Mr. Drummond McKenzie is Chief Financial Officer and Company Secretary of Tissue Therapies Ltd. Mr. McKenzie, who has been involved with Tissue Therapies since its inception, has experience in senior financial management in a range of industries including mining, financial services, health and the accounting profession, in Australia and internationally. He holds a Bachelor of Science and is Fellow of the Institute of Chartered Accountants, Fellow of the Institute of Chartered Secretaries.

Zee Upton

Ms. Zee Upton is Chief Scientific Officer of Tissue Therapies Ltd. Prof. Upton is VitroGro and oversees the Company's research activities as its Consulting Chief Scientific Officer. Prof. Upton is an biochemist and tissue engineer. She is Assistant Dean (Research) in the Faculty of Health, QUT and Leader of the Tissue Repair and Regeneration Program within the QUT Institute of Health and Biomedical Innovation.

Andrew Thelwell

Mr. Andrew Thelwell serves as Managing Director - EU Commercial Operations of Tissue Therapies Ltd. Mr Thelwell has over twenty five years experience in the wound sector, working for Smith & Nephew and ConvaTec. Previous roles have included General Management within both the Benelux and the United Kingdom & Ireland regions, and leadership of global marketing functions. He holds Bachelor of Arts and Master of Business Administration.

Eva-Lisa Heinrichs

Ms. Eva-Lisa Heinrichs serves as Medical Director - Global Medical Affairs of Tissue Therapies Ltd. Dr Heinrichs has over 16 years of experience in the medical device industry, including 4 years as Chief Medical Officer of Orteq Limited, a London-based privately owned orthobiologics company and 10 years as European Medical Director of ConvaTec Limited, an international wound care, skin care and stoma care devices company. Dr Heinrichs obtained her medical qualification from University of Helsinki, Finland and has a postgraduate research doctorate of medicine degree from Cardiff University in the UK.

Saskia Jo

Ms. Saskia Jo is Corporate Accountant of Tissue Therapies Ltd. She is an experienced corporate accountant with first-hand knowledge of implementing and modernizing financial systems that are required in an evolving company such as Tissue Therapies. She holds a Bachelors degree in Commerce, a Graduate Diploma of Applied finance and is a Certified Practicing Accountant.

Nigel Johnson

Mr. Nigel Johnson is Operations Director of Tissue Therapies Ltd. He has more than 17 years experience in the medical device and biologics industries, principally with responsibilities for development, manufacturing, quality management and regulatory affairs in Europe, Australia, Canada and the United States. He has been instrumental in the development and manufacturing of VitroGro ECM for commercial sale. He holds a Bachelor of Applied Science.

Hedie Meka

Dr. Hedie Meka is Regulatory and Intellectual Property Manager of Tissue Therapies Ltd. She has more than 6 years experience as a registered patent and trade marks attorney and prior to joining Tissue Therapies, was partly responsible for the management of Tissue Therapies’ international patents and trademarks. Earlier in her career, Dr. Meka worked as an interdisciplinary research scientist in molecular and cell biology, with experience at the University of Queensland, Imperial College, London and at Oxford University. She holds a Bachelor of Applied Science, Masters of Industrial Property, Ph.D. (Medical Science), Fellow of the Institute of Patent and Trade Mark Attorneys of Australia.

Gary Shooter

Mr. Gary Shooter serves as Director of Research and Development of Tissue Therapies Ltd. Dr Shooter is a Senior Research Fellow within the Tissue Repair and Regeneration program at QUT and has a diverse range of interests in structural biology and protein chemistry. Following his PhD, Dr Shooter has held several positions within industry and academia where he has developed a proven track record in the GMP production and characterization of protein-based therapeutics. Dr Shooter is currently co-leader of program 1 of the Wound Management and Innovation Co-operative Research Centre (CRC), alongside Professor Zee Upton.

Brian Ziegelaar

Dr. Brian Ziegelaar is serving as International Product Manager in Tissue Therapies Ltd. He has experience in the commercialization of clinical devices in his former capacity as International Product and European Sales Manager for ImpediMed Limited. Earlier in his career, Dr. Ziegelaar gained his PhD. and pursued postdoctoral research in Europe in tissue engineering and cell biology. He holds a Bachelor of Science, Master of Medical Science and a Ph.D., and pursued post-doctoral research in Europe in tissue engineering and cell biology.

Iain Ross

Mr. Iain Gladstone Ross has been Director of Tissue Therapies Ltd since May 25, 2012. He holds a Bachelor of Science in Biochemistry from the University of London. Mr. Ross has worked with multi-national companies, including Sandoz, Fisons Plc, Hoffman La Roche, and Celltech Group Plc. Over the last 15 years he has undertaken a number of company turnarounds and start-ups as a board member on behalf of both private equity groups and banks. Currently he is Chairman of Ark Therapeutics Plc (LSE), Biomer Technology Ltd , Pharminox Ltd and Coms Plc (LSE : AIM). Mr. Ross is a Non-Executive Director of Benitec BioPharma Limited (ASX) and Yellow Cross Limited, and is Vice Chairman and Trustee of Royal Holloway, University of London.

Melvyn Bridges

Dr. Melvyn (Mel) John Bridges has been Non-Executive Director of Tissue Therapies Ltd since March 12, 2009. He holds a Bachelor of Science (Chemistry) and is Fellow of the Australian Institute of Company Directors. He has experience as a CEO and Company Director in healthcare, agricultural technology, drug development, pathology, diagnostics and medical devices. Mr. Bridges has raised in excess of $300M investment capital in the healthcare/biotech sector and been directly involved in over $1B in merger and acquisition and related transactions. Mr. Bridges is Chairman of Alchemia Limited, Genetic Technologies Limited and Leaf Energy Limited and is also a Director of Benitec Biopharma Limited, ALS Limited (previously Campbell Brothers Limited) and ImpediMed Limited. He is Member of the Audit and Risk Management Committee and Member of the Remuneration Committee and Nomination Committee at the Company.

Cherrell Hirst

Dr. Cherrell Hirst has been Non-Executive Director of Tissue Therapies Ltd since June 30, 2009. She holds a Bachelor of Medicine, Bachelor of Surgery and Bachelor of Education Studies. She has had a clinical career in the detection and treatment of breast cancer and respected achievements as Director and Chair of multiple commercial, government and not-for-profit organizations. Dr. Hirst is Deputy Chair and CEO (part time) of QIC and a Director of Medibank Private Limited, Avant Mutual Group, Avant Insurance Limited, ImpediMed Limited and Xenome Limited. She has Honorary Doctorates from the University of Queensland University, Griffith University and Southern Cross University. She is Fellow of the Australian Institute of Company Directors. She is a member of the Remuneration Committee and Nomination Committee at the Company.

Basic Compensation

Search Stocks